What will happen if you take Enasidenib for three years?

Enasidenib has received widespread attention in recent years as a targeted therapy for relapsed or refractory acute myeloid leukemia (AML) harboring isocitrate dehydrogenase-2 (IDH2) mutations. Many patients consider the effects of long-term use of ensidipine and its potential effects when undergoing treatment. So, what impact will long-term use of ensidipine have on patients for three years?

First of all, the therapeutic effect of ensidipine is one of the issues that patients are most concerned about. For many AML patients with IDH2 mutations, ensidipine can help control disease progression and improve quality of life through specific targeted therapy. In clinical data, some patients can achieve long-term disease stabilization after receiving ensidipine treatment, and some patients may even achieve remission. With maintenance treatment, patients can enjoy longer survival, which undoubtedly brings positive changes to their lives.

However, long-term use of ensidipine may also be associated with certain side effects. Common side effects include abnormal liver function, leukopenia, thrombocytopenia, etc. In the case of long-term use, patients need to undergo regular blood tests to monitor changes in these indicators and ensure the safe use of the drug. In addition, patients may also experience some non-specific side effects, such as fatigue, nausea, etc. Although these reactions are mild in most cases, they may still affect the quality of life for patients undergoing long-term treatment.

It is worth noting that patients taking ensidipine for a long time also need to be alert to possible drug resistance problems. Over time, some patients may develop resistance to drugs, affecting the effectiveness of treatment. Therefore, at this point, doctors usually adjust the treatment plan in a timely manner based on the patient's physical condition and disease progression to deal with possible drug resistance issues.

Reference materials:https://www.idhifa.com/